Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.46 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Caprolactam SCHEMBL6747085 | 0.94 | FKBP5 (0.46) | OR51E2FKBP5CRBNTSHRKDM4E | |
| 2-Pyrrolidone SCHEMBL28304484 | 0.87 | OR51E2 (0.44) | OR51E2FKBP5CRBNTSHRKDM4E | |
| 2-Pyrrolidone SCHEMBL28096599 | 0.84 | OR51E2 (0.42) | OR51E2FKBP5CRBN | |
| 2-Pyrrolidone SCHEMBL2030191 | 0.81 | OR51E2 (0.39) | OR51E2FKBP5CRBN | |
| 2-Pyrrolidone SCHEMBL27469716 | 0.81 | OR51E2 (0.39) | OR51E2FKBP5CRBNTSHR | |
| SCHEMBL5604495 | 0.81 | TSHR (0.35) | TSHR | |
| 2-Pyrrolidone SCHEMBL7090022 | 0.81 | ALDH1A1 (0.52) | OR51E2FKBP5CRBNTSHRKDM4E | |
| 2-Pyrrolidone SCHEMBL8965954 | 0.78 | OR51E2 (0.48) | OR51E2FKBP5CRBNKDM4EGAA | |
| Cyclohexane SCHEMBL4358222 | 0.78 | TSHR (0.43) | TSHR | |
| 2-Pyrrolidone SCHEMBL8133376 | 0.77 | OR51E2 (0.47) | OR51E2FKBP5CRBNTSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018106666-A1 | ORAL CARE COPOLYMERS AND COMPOSITIONS AND METHODS FOR USE | ISP INVESTMENTS LLC (US) | 2018-06-14 | — | — | WO | claimed |
| EP-3377549-B1 | PROLIFEROUS POLYMERS COMPRISING LACTAMIC MOIETIES | ISP INVESTMENTS LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-10844154-B2 | Proliferous copolymers comprising lactamic moieties | ISP INVESTMENTS LLC (US) | 2020-11-24 | — | — | US | disclosed |
| US-20180369120-A1 | FRAGRANCE DELIVERY COMPOSITION COMPRISING COPOLYMERS OF ACRYLOYL LACTAM AND ALKYLMETHACRYLATES, PROCESS FOR PREPARING THE SAME, AND METHOD OF USE THEREOF | ISP INVESTMENTS LLC (US) | 2018-12-27 | — | — | US | disclosed |
| US-20180340034-A1 | PROLIFEROUS COPOLYMERS COMPRISING LACTAMIC MOIETIES | ISP INVESTMENTS LLC (US) | 2018-11-29 | — | — | US | disclosed |
| US-10118981-B2 | Lactamic polymer containing an acetoacetate moiety | ISP INVESTMENTS LLC (US) | 2018-11-06 | — | — | US | disclosed |
| EP-3377548-A1 | FRAGRANCE DELIVERY COMPOSITION COMPRISING COPOLYMERS OF ACRYLOYL LACTAM AND ALKYLMETHACRYLATES, PROCESS FOR PREPARING THE SAME, AND METHOD OF USE THEREOF | ISP Investments LLC (US) | 2018-09-26 | — | — | EP | disclosed |
| EP-3377549-A1 | PROLIFEROUS POLYMERS COMPRISING LACTAMIC MOIETIES | ISP Investments LLC (US) | 2018-09-26 | — | — | EP | disclosed |
| WO-2018106666-A1 | ORAL CARE COPOLYMERS AND COMPOSITIONS AND METHODS FOR USE | ISP INVESTMENTS LLC (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20170073447-A1 | POLYMERS CONTAINING AN ACETOACETATE MOIETY | ISP INVESTMENTS LLC (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170022313-A1 | LACTAMIC POLYMER CONTAINING AN ACETOACETATE MOIETY | ISP INVESTMENTS LLC (US) | 2017-01-26 | — | — | US | disclosed |
| US-9505862-B2 | Polymers containing an acetoacetate moiety | ISP INVESTMENTS LLC (US) | 2016-11-29 | — | — | US | disclosed |
| US-9464151-B2 | Lactamic polymer containing an acetoacetate moiety | ISP INVESTMENTS LLC (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150005465-A1 | POLYMERS CONTAINING AN ACETOACETATE MOIETY | AVOCA LLC | 2015-01-01 | — | — | US | disclosed |
| US-20140296441-A1 | LACTAMIC POLYMER CONTAINING AN ACETOACETATE MOIETY | ISP INVESTMENTS INC (US) | 2014-10-02 | — | — | US | disclosed |
| US-20130261268-A1 | LACTAMIC POLYMER CONTAINING AN ACETOACETATE MOIETY | ISP INVESTMENTS INC (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2627706-A2 | LACTAMIC POLYMERS CONTAINING AN ACETOACETATE MOIETY | Isp Investments Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| WO-2013103528-A1 | POLYMERS CONTAINING AN ACETOACETATE MOIETY | ISP INVESTMENTS INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| WO-2012148533-A1 | LACTAMIC POLYMERS CONTAINING AN ACETOACETATE MOIETY | ISP INVESTMENTS INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012051153-A2 | LACTAMIC POLYMERS CONTAINING AN ACETOACETATE MOIETY | ISP INVESTMENTS INC. (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369120-A1 | FRAGRANCE DELIVERY COMPOSITION COMPRISING COPOLYMERS OF ACRYLOYL LACTAM AND ALKYLMETHACRYLATES, PROCESS FOR PREPARING THE SAME, AND METHOD OF USE THEREOF | ALK, APH1A, CUTA | OR51E2 59/4885FKBP5 1930/4885CRBN 911/4885 |
| US-10844154-B2 | Proliferous copolymers comprising lactamic moieties | PCNA, MKI67, CCNA1 | OR51E2 4395/4885FKBP5 180/4885CRBN 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.